Katharina Kreymborg

Katharina Kreymborg is an experienced leader in the biotech and pharmaceutical sectors, currently serving as SVP - CSO Partner Team at Curie.Bio and a member of the Therapeutic Innovation Board at Cancer Research Horizons. With a strong background in cancer immunotherapy, Kreymborg has held significant roles at Versant Ventures as Principal, where responsibilities included evaluating investment opportunities and company creation. Previous experience at MorphoSys involved leading lead discovery and external innovation research, while at Roche, Kreymborg directed a department focused on cancer immunotherapeutics and pre-clinical drug development. Academic contributions include a lecturer position at the University of Applied Sciences Weihenstephan-Triesdorf and a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center. Kreymborg holds advanced degrees in Immunology from the University of Zurich and the University of Tübingen, complemented by additional business education in venture capital and bio-pharma innovation.